Provided by Tiger Fintech (Singapore) Pte. Ltd.

Akebia Therapeutics

2.40
+0.14006.19%
Pre-market: 2.34-0.0600-2.50%05:03 EDT
Volume:4.62M
Turnover:10.59M
Market Cap:566.40M
PE:-10.50
High:2.40
Open:2.25
Low:2.18
Close:2.26
Loading ...

US$7.83 - That's What Analysts Think Akebia Therapeutics, Inc. (NASDAQ:AKBA) Is Worth After These Results

Simply Wall St.
·
16 Mar

Akebia Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
14 Mar

Akebia Therapeutics’ Strong Market Performance and Strategic Initiatives Drive Buy Rating

TIPRANKS
·
14 Mar

Akebia Therapeutics Price Target Maintained With a $7.50/Share by HC Wainwright & Co.

Dow Jones
·
14 Mar

Akebia Therapeutics Inc (AKBA) Q4 2024 Earnings Call Highlights: Navigating Revenue Declines ...

GuruFocus.com
·
14 Mar

Akebia Therapeutics Faces Global Regulatory Challenges Amid Brexit and EU Changes

TIPRANKS
·
14 Mar

Akebia Therapeutics Shares Fall After Q4 Results

MT Newswires Live
·
14 Mar

Akebia Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
13 Mar

Akebia Therapeutics (AKBA) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
13 Mar

Akebia Therapeutics: Q4 Earnings Snapshot

Associated Press Finance
·
13 Mar

Akebia's Cash And Cash Equivalents As Of December 31, 2024, Were Approximately $51.9M That Will Be Sufficient To Fund Current Operating Plan For At Least Two Years

Benzinga
·
13 Mar

Akebia Therapeutics Q4 2024 GAAP EPS $(0.10) Misses $(0.08) Estimate, Sales $46.50M Beat $37.35M Estimate

Benzinga
·
13 Mar

Akebia Therapeutics: Cash Resources & Cash From Ops to Fund Current Operating Plan for at Least 2 Years

THOMSON REUTERS
·
13 Mar

Akebia Therapeutics: Expect Vafseo Q1 2025 Net Product Revenues of About $10 Mln-$11 Mln

THOMSON REUTERS
·
13 Mar

Akebia Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Vafseo® (vadadustat) Commercial Launch Progress Update

GlobeNewswire
·
13 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
11 Mar